Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders

• Multiple KOLs highlight varoglutamstat pathology, clinical development and clinical applicability of key endpoints in VIVIAD study
• VIVIAD progressing as planned with final results expected Q1/2024

Halle (Saale) / Munich, Germany, October 17, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual R&D Event with Key Opinion Leaders (KOLs), focusing on the Company’s lead program, varoglutamstat, and VIVIAD, a state-of-the-art Phase 2b study being conducted in Europe and designed to evaluate its safety, tolerability, and efficacy in 259 (final number of randomized participants) subjects with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD).

The event, which was moderated by Philip Scheltens, M.D., Ph.D., EQT Life Sciences Dementia Fund, featured presentations from Stephan Schilling, Ph.D., Fraunhofer Institute for Cell Therapy and Immunology, John Harrison, Ph.D., Scottish Brain Sciences, Sietske Sikkes, Ph.D., Alzheimer Center at Amsterdam UMC, Willem de Haan, M.D., Ph.D., Alzheimer Center at Amsterdam UMC, and Vivoryon Chief Executive Officer (CEO), Frank Weber, M.D.

“We are pleased to have hosted so many renowned KOLs as we discussed multiple important facets of varoglutamstat’s clinical development, its pathology and the clinical utility of primary and secondary endpoints of the VIVIAD study. We have taken a meticulous and well thought out approach to the VIVIAD trial design and believe that the primary endpoint, Cogstate NTB (neurological test battery), represents the top standard in assessing cognition,” said Frank Weber, M.D., CEO of Vivoryon. “While significant advancements have been made for AD patients, we believe that varoglutamstat has the potential to address vast unmet need by providing patients with an easy to administer, oral small molecule. We look forward to the final readout of VIVIAD in the first quarter of next year.“